Cargando…
Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients
Autores principales: | Amit, Sharon, Regev-Yochay, Gili, Afek, Arnon, Kreiss, Yitshak, Leshem, Eyal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7906709/ https://www.ncbi.nlm.nih.gov/pubmed/33610193 http://dx.doi.org/10.1016/S0140-6736(21)00448-7 |
Ejemplares similares
-
COVID-19 vaccine efficacy data: solid enough to delay second dose? – Authors' reply
por: Amit, Sharon, et al.
Publicado: (2021) -
Decreased infectivity following BNT162b2 vaccination: A prospective cohort study in Israel
por: Regev-Yochay, Gili, et al.
Publicado: (2021) -
Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection
por: Nemet, Ital, et al.
Publicado: (2021) -
Six-Month Follow-up after a Fourth BNT162b2 Vaccine Dose
por: Canetti, Michal, et al.
Publicado: (2022) -
High Immune Response Rate to the Fourth Boost of the BNT162b2 Vaccine against the Omicron Variants of Concern among Liver Transplant Recipients
por: Davidov, Yana, et al.
Publicado: (2022)